Table 1 Anti-NMDA-R follow-up of the titration in CSF and in serum (qualitative and quantitative)
From: Extensive myelitis associated with anti-NMDA receptor antibodies
Date | Jun 23rd | Jul 2nd | Jul 10th | Jul 11th | Jul 14th | Jul 16th | Jul 17th | Jul 23rd | Jul 30th | Aug 6th | Aug 13th | Oct 17th |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CSF | + (1/10) | + (low) | NA | NA | NA | NA | - | NA | NA | NA | NA | - |
Anti-NMDA-R in serum | NA | NA | + (1/10) | + (1/10) | - | + (low) | - | - | + (low) | NA | + (1/10) | - |
Methylprednisolone (1 g/day IV) | 3 days | 5 days | ||||||||||
PLEX | Yes | Yes | Yes | Yes | Yes | |||||||
Rituximab (375 mg/m2/week during 4 weeks) | Yes | Yes | Yes | Yes |